By Ludwig Burger GSK on Thursday lifted its medium-term growth forecast for its HIV drugs business ViiV, encouraged by strong sales of long-acting injections that aim to replace daily pills forNS child killer Penny Boudreau and the path to eventual release | SaltWireGSK on Thursday lifted its medium-term growth forecast for its HIV drugs business ViiV, encouraged by strong sales of long-acting injections that aim to replace daily pills for preventing and treating the infection.
The HIV business, the focus of a GSK's capital markets day on Thursday, is now targeting annual rates of sales growth of between 6% and 8%, to reach between 6 billion pounds and 7 billion pounds in 2026, up from"mid-single-digit" percentage growth seen previously. In the prevention setting, known as pre-exposure prophylaxis, GSK's Apretude competes with Gilead's daily pill, Truvada, and a cheaper generic version sold by Teva as Atripla.
ایران آخرین اخبار, ایران سرفصلها
Similar News:همچنین می توانید اخبار مشابهی را که از منابع خبری دیگر جمع آوری کرده ایم، بخوانید.
منبع: SaltWire Network - 🏆 45. / 63 ادامه مطلب »